Evaluating the Effectiveness of Statin Therapy in Reducing the Risk of Ischemic and Hemorrhagic Stroke Among Patients with Atrial Fibrillation: A Meta-Analysis of Randomized Controlled Trials and Observational Studies
DOI:
https://doi.org/10.70749/ijbr.v3i4.1058Keywords:
Statins, Atrial Fibrillation, Ischemic Stroke, Hemorrhagic Stroke, Meta-AnalysisAbstract
Background: Atrial fibrillation (AF) is a significant risk factor for both ischemic and hemorrhagic strokes. Although statins are widely recognized for their lipid-lowering and anti-inflammatory effects, their specific role in stroke prevention among AF patients remains uncertain. This meta-analysis aims to evaluate the effectiveness of statin therapy in reducing the risk of ischemic and hemorrhagic stroke in individuals with AF. Methods: A systematic search of PubMed, Embase, Cochrane Library, and Scopus was conducted for studies published between January 2000 and March 2024. Eligible studies included randomized controlled trials (RCTs) and observational cohorts that assessed stroke outcomes in AF patients receiving statins versus control. Data were extracted and pooled using a random-effects model. Risk ratios (RRs) and 95% confidence intervals (Cis) were calculated, and heterogeneity was assessed using the I² statistic. Risk of bias was evaluated using the Cochrane Risk of Bias tool and Newcastle-Ottawa Scale. Results: Four studies (three RCTs and one observational cohort) with a combined sample size of over 32,000 participants were included. The pooled analysis demonstrated a statistically significant reduction in stroke risk with statin use (RR: 0.76; 95% CI: 0.64–0.90; I² = 51%). No significant increase in hemorrhagic stroke risk was observed. Most included studies showed low to moderate risk of bias, and funnel plots indicated minimal publication bias.
Conclusion: Statin therapy is associated with a significant reduction in overall stroke risk, particularly ischemic stroke, among patients with atrial fibrillation. These findings support the potential role of statins as an adjunctive preventive strategy in AF management. Further high-quality RCTs are warranted to confirm these results and explore optimal statin regimens.
Downloads
References
Chugh, S. S., Havmoeller, R., Narayanan, K., Singh, D., Rienstra, M., Benjamin, E. J., Gillum, R. F., Kim, Y., McAnulty, J. H., Zheng, Z., Forouzanfar, M. H., Naghavi, M., Mensah, G. A., Ezzati, M., & Murray, C. J. (2013b). Worldwide Epidemiology of Atrial Fibrillation. Circulation, 129(8), 837–847. https://doi.org/10.1161/circulationaha.113.005119
Wolf, P. A., Abbott, R. D., & Kannel, W. B. (1991). Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke, 22(8), 983–988. https://doi.org/10.1161/01.str.22.8.983
Kirchhof, P., Benussi, S., Kotecha, D., Ahlsson, A., Atar, D., Casadei, B., Castella, M., Diener, H., Heidbuchel, H., Hendriks, J., Hindricks, G., Manolis, A. S., Oldgren, J., Popescu, B. A., Schotten, U., Van Putte, B., Vardas, P., Agewall, S., Camm, J., . . . Zeppenfeld, K. (2016). 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. European Journal of Cardio-Thoracic Surgery, 50(5), e1–e88. https://doi.org/10.1093/ejcts/ezw313
Davignon, J. (2004). Beneficial cardiovascular pleiotropic effects of statins. Circulation, 109(23_suppl_1). https://doi.org/10.1161/01.cir.0000131517.20177.5a
Amarenco, P., Bogousslavsky, J., Callahan, A., Goldstein, L. B., Hennerici, M., Rudolph, A. E., Sillesen, H., Simunovic, L., Szarek, M., Welch, K. M. A., & Zivin, J. A. (2006c). High-Dose Atorvastatin after Stroke or Transient Ischemic Attack. New England Journal of Medicine, 355(6), 549–559. https://doi.org/10.1056/nejmoa061894
Choi, K., Seo, W., Park, M., Kim, J., Chung, J., Bang, O. Y., Kim, G., Song, T., Kim, B. J., Heo, S. H., Jung, J., Oh, K., Kim, C. K., Yu, S., Park, K., Kim, J., Park, J., Choi, J. C., Hwang, Y., & Kim, Y. (2019). Effect of statin therapy on outcomes of patients with acute ischemic stroke and atrial fibrillation. Journal of the American Heart Association, 8(24). https://doi.org/10.1161/jaha.119.013941
Eun, M., Jung, J., Choi, K., & Seo, W. (2020b). Statin Effects in Atrial Fibrillation-Related Stroke: A Systematic Review and Meta-Analysis. Frontiers in Neurology, 11. https://doi.org/10.3389/fneur.2020.589684
Pastori, D., Baratta, F., Di Rocco, A., Farcomeni, A., Del Ben, M., Angelico, F., Violi, F., Pignatelli, P., & Lip, G. Y. (2021b). Statin use and mortality in atrial fibrillation: A systematic review and meta-analysis of 100,287 patients. Pharmacological Research, 165, 105418. https://doi.org/10.1016/j.phrs.2021.105418
Ridker, P. M., Danielson, E., Fonseca, F. A., Genest, J., Gotto, A. M., Kastelein, J. J., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., Nordestgaard, B. G., Shepherd, J., Willerson, J. T., & Glynn, R. J. (2008c). Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein. New England Journal of Medicine, 359(21), 2195–2207. https://doi.org/10.1056/nejmoa0807646
Ridker, P. M., & Cook, N. R. (2013). Statins: new American guidelines for prevention of cardiovascular disease. The Lancet, 382(9907), 1762–1765. https://doi.org/10.1016/s0140-6736(13)62388-0
Eun, M., Jung, J., Choi, K., & Seo, W. (2020). Statin Effects in Atrial Fibrillation-Related Stroke: A Systematic Review and Meta-Analysis. Frontiers in Neurology, 11. https://doi.org/10.3389/fneur.2020.589684
Pastori, D., Baratta, F., Di Rocco, A., Farcomeni, A., Del Ben, M., Angelico, F., Violi, F., Pignatelli, P., & Lip, G. Y. (2021). Statin use and mortality in atrial fibrillation: A systematic review and meta-analysis of 100,287 patients. Pharmacological Research, 165, 105418. https://doi.org/10.1016/j.phrs.2021.105418
Ridker, P. M., Danielson, E., Fonseca, F. A., Genest, J., Gotto, A. M., Kastelein, J. J., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., Nordestgaard, B. G., Shepherd, J., Willerson, J. T., & Glynn, R. J. (2008b). Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein. New England Journal of Medicine, 359(21), 2195–2207. https://doi.org/10.1056/nejmoa0807646
Amarenco, P., Bogousslavsky, J., Callahan, A., Goldstein, L. B., Hennerici, M., Rudolph, A. E., Sillesen, H., Simunovic, L., Szarek, M., Welch, K. M. A., & Zivin, J. A. (2006b). High-Dose Atorvastatin after Stroke or Transient Ischemic Attack. New England Journal of Medicine, 355(6), 549–559. https://doi.org/10.1056/nejmoa061894
Amarenco, P., Bogousslavsky, J., Callahan, A., Goldstein, L. B., Hennerici, M., Rudolph, A. E., Sillesen, H., Simunovic, L., Szarek, M., Welch, K. M. A., & Zivin, J. A. (2006). High-Dose Atorvastatin after Stroke or Transient Ischemic Attack. New England Journal of Medicine, 355(6), 549–559. https://doi.org/10.1056/nejmoa061894
Ridker, P. M., Danielson, E., Fonseca, F. A., Genest, J., Gotto, A. M., Kastelein, J. J., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., Nordestgaard, B. G., Shepherd, J., Willerson, J. T., & Glynn, R. J. (2008). Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein. New England Journal of Medicine, 359(21), 2195–2207. https://doi.org/10.1056/nejmoa0807646
Féasson, S. (2002). MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial. The Lancet, 360(9326), 7–22. https://doi.org/10.1016/s0140-6736(02)09327-3
Shweikialrefaee, B., Ko, D. T., Fang, J., Pang, A., Austin, P. C., Dorian, P., Singh, S. M., Jackevicius, C. A., Tu, K., Lee, D. S., & Abdel‐Qadir, H. (2023). Statin use and stroke rate in older adults with atrial fibrillation: A Population‐Based Cohort study. Journal of the American Heart Association, 12(12). https://doi.org/10.1161/jaha.122.028381
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Indus Journal of Bioscience Research
This work is licensed under a Creative Commons Attribution 4.0 International License.
